Horizon’s TurboGFP tagged HAP1 has been included in The Scientist’s Top 10 Innovations of 2016
Horizon now has four of these innovation award winning products in its portfolio
Cambridge, UK, 05 December 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), the world leader in the application of gene editing technologies, today announced leading industry publication The Scientist has included one of its portfolio products in its ‘Top 10 Innovations’ list for the fourth year in a row.
The latest product to have been chosen by a panel of expert judges to be included in The Scientist’s Top 10 innovations, Horizon’s TurboGFP tagged HAP1 cell lines, enables researchers to study proteins at the endogenous level in live cell assays. The cells combine three leading technologies: CRISPR Cas9 gene editing; the HAP1 cell line; and TurboGFP™, an early maturation fluorescence protein from Evrogen.
Although gene editing techniques and technologies are now readily available, the processes are still not straightforward, and can be costly in terms of time and resources. All of the award-winning products in Horizon’s portfolio have been designed to provide researchers with access to the latest gene editing technologies, effectively democratising gene editing. These products enable scientists to quickly confirm their findings or advance their theories using Horizon’s highly characterised gene-edited cell lines.
Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented: “We are delighted that cutting edge technology provided by Horizon, a Cambridge based biotech, is being recognised at the international level, and is assisting scientists worldwide to further their research. To have products included in the Top 10 Innovations of the year for the fourth time illustrates Horizon’s continued dedication to innovation, and developing world leading gene editing products and services.”
